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(HSCT) patient. The degree of immune suppression appears to be
the most important risk factor for development of serious adeno-
viral disease. While withdrawal of immune suppression, and the
use of cidofovir may have some effect in reducing viral load and
hastening immune recovery, these approaches have appreciable
side effects and are not always effective. Little is known about the
reconstitution of immunity to adenovirus after HSCT. Therefore,
in this current study we have prospectively monitored the recovery
of adenovirus cellular immunity in pediatric HSCT patients re-
ceiving matched-related, mismatched related or unrelated donor
grafts. 23 pediatric HSCT patients (age range 14 months-20 years)
were enrolled on this study which aims to monitor viral load and
recovery of cellular immunity to adenovirus post HSCT. We have
developed and validated a real-time PCR (Q-PCR) to obtain a
quantitative measure of viral load. Q-PCR is more sensitive than
semi-quantitative PCR and shows that adenovirus can be detected
(despite the absence of symptoms) in the blood, stool or urine at
rates of up to 70%. 22 patients have30 days follow-up (mean 147
days, range 60–240 days). 18/22 (81%) have had detectable levels
of adenoviral DNA in stool (14/18) or blood (13/18). Positivity in
the stool usually preceded adenovirus detection in the blood. 3
patients were exclusively positive in the blood on one occasion with
low viral copy number (range 650 to 1200 copies/ml). 8 patients
have had multiple blood samples positive for adenovirus DNA
ranging in peak viral copy concentration from 1200 to 92500 cp/ml
(mean 31056 cp/ml). Peak copy number in the stool ranged from
1  103 to 9  109 cp/gram stool. In a preliminary analysis rising
levels appear to correlate with risk of infection. ELISPOT assay
and tetramer analysis for known HLA-restricted adenovirus
epitopes will be used to monitor recovery of adenovirus speciﬁc
T-cells in these patients. The results from this study will, therefore
provide critical information for our forthcoming clinical trial
where we will evaluate if immunity to adenovirus can be improved
by adoptive transfer of adenovirus speciﬁc CTLs generated by
culture with monocytes transduced with an Ad5/35 adenoviral
vector (Leen et al, Blood 2004;104:2432–40).
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THE EFFECTS OF CYTOTOXIC AND IMMUNOSUPPRESSIVE AGENTS ON
THYMIC RECONSTITUTION
Prockop, S.E.1; O’Reilly, R.J.1; Petrie, H.T.2 1. Memorial Sloan Ket-
tering Cancer Center, New York, NY; 2. University of Miami School of
Medicine, Miami, FL.
One key component of long-term outcome after stem cell trans-
plant (SCT) is successful reconstitution of the immune system. In
this regard, effective reconstitution of antigen-speciﬁc immunity
requires de novo T cell generation. Bone marrow derived progen-
itors seed the thymus and undergo a complex process involving
lineage commitment, proliferation and selection. Coordinated in-
teraction of marrow-derived lymphoid progenitors with thymic
stromal cells is required for successful T lymphopoiesis in the
post-natal thymus. Disruption of the thymic microenvironment
can result in disrupted T cell lymphopoiesis. One cause of pro-
longed defects in generating functional T lymphocytes after SCT
is damage to the thymic microenvironment by radiation or cyto-
toxic therapy. Speciﬁc damage to the thymic microenvironment by
the individual agents used in both myeloablative and non-myeloa-
blative regimens has not been fully evaluated. We have developed
a model system using immunodeﬁcient mice as a platform on
which to assess thymic reconstitution. The thymus of mice deﬁ-
cient for the alpha chain of the IL-7 receptor (IL7R/) can be
reconstituted by the injection of low doses of wild type bone
marrow. The ability to achieve this reconstitution appears to de-
pend on absolute numbers of early intra-thymic precursors, rather
than on total thymic cellularity. Exploiting this model, the ade-
quacy of thymic reconstitution following the administration of
cytotoxic and immunosuppressive agents can be compared to the
thymic reconstitution that occurs in the absence of agents poten-
tially toxic to the thymic stroma. Our model system allows the
evaluation of thymic reconstitution after single agent regimens
insufﬁcient to allow donor cell engraftment in wild type mice. The
effects of several agents on thymic reconstitution will be presented.
In addition we have identiﬁed morphologic consequences of spe-
ciﬁc ablative agents and a phenotype of abnormally developing T
lymphocytes that is speciﬁc to injury from busulfan. It is antici-
pated that this information will lead to strategies to both minimize
delayed immune reconstitution and to augment T cell lymphopoi-
esis post-transplant. In addition, further evaluation of impaired
thymic reconstitution will augment the understanding of lym-
phostromal interactions crucial to normal T cell lymphopoiesis.
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TRANSPLANT FOR LYMPHOPROLIFERATIVE DISORDERS
Hill, J.M.1; Webber, S.M.2; Fitzmaurice, T.F.1; Cole, B.F.2; Szczepi-
orkowski, Z.M.1; Meehan, K.R.1 1. Dartmouth-Hitchcock Medical Cen-
ter, Lebanon, NH; 2. Dartmouth Medical School, Hanover, NH.
Increasing data now exists to substantiate early absolute lympho-
cyte count (ALC) recovery following both allogeneic and autolo-
gous stem cell transplant as a strong prognostic indicator for
survival, particularly with lymphoproliferative disorders (Myeloma
and Lymphoma). Yet, there is still a paucity of insight into speciﬁc
factors affecting the ALC. Furthermore, the level and time of
optimal lymphocyte recovery reported has varied, ranging between
500–1000 cells/mcl at days 15–25 after transplant. Based on the
above, we performed a retrospective analysis of 59 patients with
Myeloma and Lymphoma (HD and NHL) who had undergone
high-dose chemotherapy and autologous stem cell transplant at
Dartmouth-Hitchcock Medical Center during 2002–2004 to assess
potential factors that might correlate with the ALC. For this
analysis, ALC thresholds of 500 on day 15 (ALC-15) and
1000 on day 25 (ALC-25) post-transplant were included, and
correlated with the following four parameters: 1) age; 2) number of
pre-transplant regimens; 3) dose of CD34 cells/kg recipient in-
fused; 4) 	 IL-2 post-transplant. By both univariate and multivar-
iate analysis, no statistically signiﬁcant correlation was found be-
tween the above four parameters and attainment of ALC-15 500
or ALC-25 1000. A trend toward statistical signiﬁcance was
noted for patients receiving 5  106 CD34 cells/kg or for those
receiving post-transplant IL-2. Given the limitations of a retro-
spective analysis, a follow-up prospective assessment of ALC de-
terminants (both clinical and laboratory) during immune reconsti-
tution after transplant is planned. Hopefully, this will help to
clarify optimal transplant conditions for patients with lymphopro-
liferative disorders as well as to elucidate speciﬁc immunologic
events involved in this early lymphocyte recovery that provide the
basis for a post-transplant survival beneﬁt, presumably via im-
proved immune surveillance against infection and minimal residual
disease.
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THYMIC ACTIVITY OF HUMAN GROWTH HORMONE ON MURINE THY-
MOCYTES: POTENTIAL ROLE IN PROMOTING THYMOPOIESIS FOLLOW-
ING BONE MARROW TRANSPLANT
Welniak, L.A.1; Charter, N.S.1; Murphy, W.J.2 1. University of Ne-
vada School of Medicine, Reno, NV; 2. Nevada Cancer Institute, Reno,
NV.
Thus far, very few agents have been demonstrated to positively
affect thymic function. Many cytokines have been shown to pro-
mote peripheral T cell function but only a select few (i.e. IL-7 and
SCF) have been shown to promote thymopoiesis or T progenitor
cell survival. Most cytokines were meant to exert local effects and
it is often difﬁcult to generate the levels needed after systemic
administration to yield sustained biological effects. Hormones, by
their very nature, are well suited for systemic administration. Neu-
roendocrine hormones such as growth hormone (GH) and prolac-
tin (PRL) have long been associated with effects on immune cell
function. We have shown that administration of recombinant hu-
man GH (rhGH) results in the enhanced recovery of thymopoiesis
following murine syngeneic bone marrow transplants. To explore
the mechanism of action, we investigated the effects of GH on
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